Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Workday Inc (WDAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Workday Inc — how do they compare? Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B), while Workday Inc trades at $188.03 (market cap $44.41B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.9× Workday Inc's market cap, and Vertex Pharmaceuticals Incorporated is more actively traded (806,603 versus 1,519,068). Which is the better fit depends on your goals — on Pluang, investors hold Vertex Pharmaceuticals Incorporated for 120 Days and Workday Inc for 38 Days on average.
| VRTX | WDAY | |
|---|---|---|
Market Cap | $128.16B | $44.41B |
Volume | 806,603 | 1,519,068 |
Sector | Health | Technology |
52-Week High | $557.96 | $245.67 |
52-Week Low | $407.37 | $112.55 |
Typical Hold Time | 120 Days | 38 Days |
Enterprise Value | $122.29B | $44.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Workday (WDAY) trades at $187.81, up 0.68% with a bearish technical signal despite recent earnings beats. The company shows strong revenue growth from $8.45B in 2025 to $10.2B projected for 2026, with net income margin improving to 12.31%. Recent developments include UAE market expansion and AI product launches, though layoffs and a fraud investigation present headwinds. Analyst consensus remains positive with a $202.92 price target.
WDAY's valuation appears stretched with a P/E of 37.53, but robust AI-driven growth and strategic partnerships support long-term upside. Key risks include integration execution, competitive pressures, and ongoing legal scrutiny. The stock offers growth exposure with moderate risk for investors comfortable with premium valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Workday Inc
Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.
Read more on WDAY →
